CXCL13 and lung adenocarcinoma: The upregulation of the RNA expression of chemokine CXCL13 (CXC-chemokine ligand 13) was correlated with a better response to ICI therapy in lung adenocarcinoma patients; however, this overexpression was not significantly associated with TMB (p = 0.054) [119].